Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
The launch of novel oral anticoagulants (NOACs), such as Bayer/Janssen’s Xarelto, Bristol-Myers Squibb/Pfizer’s Eliquis/Elicuis, and Boehringer Ingelheim’s Pradaxa/Pradaxar, in Brazil and Mexico for the treatment and prophylaxis of venous thromboembolism (VTE) and stroke prevention in atrial fibrillation (AF) has expanded the market landscape and given physicians alternatives to the more traditional anticoagulation strategies. Further, anticipated use of NOACs in the prevention of thrombotic episodes in acute coronary syndrome (ACS) will possibly enlarge the list of approved indications for some of these agents. However, successful uptake of NOACs depends highly on securing formulary coverage across healthcare programs in Brazil and Mexico, and the NOACs’ premium-price tag poses a major challenge to these cost-contained healthcare systems.
Decision Resources Group’s Emerging Markets Physician & Payer Forum report “Novel Oral Anticoagulants in LATAM (Brazil and Mexico): Physician and Payer Perspectives on the Evolving Treatment of Venous Thromboembolism, Atrial Fibrillation, and Acute Coronary Syndrome” surveys 100 cardiologists and interviews 6 payers in Brazil and Mexico to explore how both parties shape the prescribing and access environment for currently approved brands for VTE, AF, and ACS. In addition, it assesses how the anticoagulation market will evolve in the next three years as the anticoagulation armamentarium expands in these two countries. Interviewed payers include the following:
- Brazil: Head of the pharmaceutical division of Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP) (reference for the MoH and CONITEC for development of protocols); director of pharmaceutical assistance and representative of HC pharmacy in the therapeutic committee of the Department of Health of the São Paulo State; cardiologist KOLs; members of the P&T committees at Incor (Instituto do Coração), ICESP (Instituto do Câncer do Estado de São Paulo), and private hospitals with broad experience in the standardization of drugs and development of protocols in the public and private sector.
- Mexico: Subdirector of healthcare agreements, OPD (Organismo Provincial de Desarrollo) Northern Region, MoH (accountable for administration of all healthcare agreements and healthcare resources provided by the federal government at the state level, including for Seguro Popular); national coordinator of special programs, including cardiology, at the Sub-Direction of Hospital Regulation of the Medical Department of ISSSTE; cardiologist KOL at the National Institute of Cardiology and member of the Mexican Society Of Cardiology; editor of the Mexican Archives of Cardiology.
Already a Client? Log in to access this report.